A personalized approach to acute myeloid leukemia therapy: current options

Therapeutic options for acute myeloid leukemia (AML) have remained unchanged for nearly the past 5 decades, with cytarabine and anthracyclines and use of hypomethylating agents for less intensive therapy. Implementation of large-scale genomic studies in the past decade has unraveled the genetic land...

Descripción completa

Detalles Bibliográficos
Autores principales: Illangeswaran, Raveen Stephen Stallon, Das, Saswati, Paul, Daniel Zechariah, Mathews, Vikram, Balasubramanian, Poonkuzhali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6684879/
https://www.ncbi.nlm.nih.gov/pubmed/31447578
http://dx.doi.org/10.2147/PGPM.S168267

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6684879/
https://www.ncbi.nlm.nih.gov/pubmed/31447578
http://dx.doi.org/10.2147/PGPM.S168267

Ejemplares similares